ONPATTRO® (patisiran)

Indicated in the UK for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Click here to view SmPC ›
ONPATTRO (patisiran) Prescribing Information ›

AMVUTTRA®▼(vutrisiran)

Indicated in the UK for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients with stage 1 or stage 2 polyneuropathy, as well as for wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy.

Click here to view SmPC ›
AMVUTTRA (vutrisiran) Prescribing Information ›

GIVLAARI®▼(givosiran)

Indicated in the UK for the treatment of Acute Hepatic Porphyria (AHP) in adults and adolescents aged 12 years and older.

Click here to view SmPC ›
GIVLAARI (givosiran) Prescribing Information ›

OXLUMO® (lumasiran)

Indicated in the UK for the treatment of Primary Hyperoxaluria Type 1 (PH1) in all age groups.

Click here to view SmPC ›
OXLUMO (lumasiran) Prescribing Information ›

Reporting of Adverse Events

Adverse events should be reported. Reporting forms and information can be found at the Medicines and Healthcare Regulatory Authority, via the Yellow Card Scheme, Website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store for the UK. Suspected adverse events can also be reported by calling the Yellow Card reporting line, for free, on 0800 731 6789.

When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset timing, treatment dates, and product brand name.

For medical information or to report an adverse event or product complaint to Alnylam:

Toll: +44 (0) 1628 878 592
Toll-free: 0800 141 2569 (also hidden caller ID)
Email: medinfo@alnylam.com

Corp-UK-00097 | February 2026